Am J Perinatol 2014; 31(01): 055-060
DOI: 10.1055/s-0033-1334452
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Spontaneous Preterm Birth in African-American and Caucasian Women Receiving 17α-Hydroxyprogesterone Caproate

Julia Timofeev
1   Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, Washington, District of Columbia
,
Jasbir Singh
1   Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, Washington, District of Columbia
,
Niki Istwan
2   Department of Clinical Research, Alere Health, Women's and Children's Health, Atlanta, Georgia
,
Debbie Rhea
2   Department of Clinical Research, Alere Health, Women's and Children's Health, Atlanta, Georgia
,
Rita W. Driggers
1   Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, Washington, District of Columbia
› Author Affiliations
Further Information

Publication History

20 September 2012

02 January 2013

Publication Date:
01 March 2013 (online)

Abstract

Objective To determine if the rates of recurrent spontaneous preterm birth in women receiving 17α-hydroxyprogesterone caproate (17P) differ according to maternal race.

Study Design Retrospective analysis of a cohort of women enrolled in outpatient 17P administration at < 27 weeks. Maternal characteristics, obstetric history, and rates of recurrent preterm birth were determined using chi-square and multivariable Cox proportional hazards regression at two-tailed α = 0.05. Primary study outcome was defined as having a spontaneous preterm birth < 34 weeks.

Results African-American women initiated 17P injections later (19.6 versus 18.9 weeks, p < 0.001) and discontinued injections earlier (33.2 versus 34.1 weeks, p < 0.001) than Caucasian women. Spontaneous recurrent preterm birth < 34 weeks was higher in African-Americans versus Caucasians receiving 17P (odds ratio 2.1; 95% confidence interval 1.7, 2.4). After adjusting for other significant factors, African-American race retained the strongest association with recurrent spontaneous preterm birth < 34 weeks. Within each racial group, short cervical length < 25 mm before 27 weeks' gestation had the highest hazard of recurrent spontaneous preterm delivery.

Conclusion Despite treatment with 17P, African-American women have higher rates of recurrent preterm birth.

Note

Reprint requests not available.


Presented at the 32nd Annual Meeting of the Society for Maternal-Fetal Medicine, Dallas, Texas, February 10, 2012.


 
  • References

  • 1 Hamilton BE, Martin JA, Ventura SJ. Births: Preliminary data for 2010. National Vital Statistics Reports web release; vol 60 no 2. Hyattsville, MD: National Center for Health Statistics; 2011. . Accessed on 01/10/2012 at: http://www.cdc.gov/nchs/births.htm
  • 2 Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008; 371: 75-84
  • 3 Kistka ZA, Palomar L, Lee KA , et al. Racial disparity in the frequency of recurrence of preterm birth. Am J Obstet Gynecol 2007; 196: e1-e6
  • 4 Leslie JC, Galvin SL, Diehl SJ, Bennett TA, Buescher PA. Infant mortality, low birth weight, and prematurity among Hispanic, white, and African American women in North Carolina. Am J Obstet Gynecol 2003; 188: 1238-1240
  • 5 Manuck TA, Lai Y, Meis PJ , et al. Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2011; 205: e1-e9
  • 6 Velez DR, Fortunato S, Thorsen P, Lombardi SJ, Williams SM, Menon R. Spontaneous preterm birth in African Americans is associated with infection and inflammatory response gene variants. Am J Obstet Gynecol 2009; 200: e1-e27
  • 7 Menon R, Pearce B, Velez DR , et al. Racial disparity in pathophysiologic pathways of preterm birth based on genetic variants. Reprod Biol Endocrinol 2009; 7: 62
  • 8 Goldenberg RL, Cliver SP, Mulvihill FX , et al. Medical, psychosocial, and behavioral risk factors do not explain the increased risk for low birth weight among black women. Am J Obstet Gynecol 1996; 175: 1317-1324
  • 9 American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Assessment of risk factors for preterm birth. Clinical management guidelines for obstetriciangynecologists. Number 31, October 2001. (Replaces Technical Bulletin number 206, June 1995; Committee Opinion number 172, May 1996; Committee Opinion number 187, September 1997; Committee Opinion number 198, February 1998; and Committee Opinion number 251, January 2001). Obstet Gynecol 2001; 98 (4) 709-716
  • 10 Adams MM, Elam-Evans LD, Wilson HG, Gilbertz DA. Rates of and factors associated with recurrence of preterm delivery. JAMA 2000; 283: 1591-1596
  • 11 Iams JD, Berghella V. Care for women with prior preterm birth. Am J Obstet Gynecol 2010; 203: 89-100
  • 12 Mercer BM, Goldenberg RL, Moawad AH , et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. Am J Obstet Gynecol 1999; 181 (5 Pt 1) 1216-1221
  • 13 American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Use of progesterone to reduce preterm birth. Obstet Gynecol 2003; 102 (5 Pt 1) 1115-1116
  • 14 Meis PJ, Klebanoff M, Thom E , et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379-2385
  • 15 Joy S, Rhea DJ, Istwan NB, Desch CN, Stanziano G. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention. Am J Perinatol 2010; 27: 343-348
  • 16 González-Quintero VH, Istwan NB, Rhea DJ, Smarkusky L, Hoffman MC, Stanziano GJ. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery. J Matern Fetal Neonatal Med 2007; 20: 249-252
  • 17 How HY, Barton JR, Istwan NB, Rhea DJ, Stanziano GJ. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?. Am J Obstet Gynecol 2007; 197: e1-e4
  • 18 Meis PJ, Klebanoff M, Dombrowski MP , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstet Gynecol 2005; 106: 557-561
  • 19 Caritis SN, Sharma S, Venkataramanan R , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation. Am J Obstet Gynecol 2011; 205: e1-e8
  • 20 Berghella V, Rafael TJ, Szychowski JM, Rust OA, Owen J. Cerclage for short cervix on ultrasonography in women with singleton gestations and previous preterm birth: a meta-analysis. Obstet Gynecol 2011; 117: 663-671
  • 21 Berghella V, Figueroa D, Szychowski JM , et al; Vaginal Ultrasound Trial Consortium. 17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am J Obstet Gynecol 2010; 202: e1-e6
  • 22 Polakowski LL, Akinbami LJ, Mendola P. Prenatal smoking cessation and the risk of delivering preterm and small-for-gestational-age newborns. Obstet Gynecol 2009; 114 (2 Pt 1) 318-325